Tadekinig alfa is under clinical development by AB2 Bio and currently in Phase III for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase III drugs for Hemophagocytic Lymphohistiocytosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tadekinig alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tadekinig alfa overview
Tadekinig alfa is under development for the treatment of hemophagocytic lymphohistiocytosis (XIAP deficiency), NLRC4-macrophage activation syndrome (lymphoproliferative disorders) in children and adults, unspecified cancer and COVID-19 cytokine release syndrome. The drug candidate is administered through subcutaneous route in the form of solution. It acts by targeting the cytokine interleukin-18.
The drug candidate was under development for the treatment of chronic obstructive pulmonary disorder, dry eye disease, adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (Still Disease).
AB2 Bio overview
AB2 Bio is a drug discovery and development company focused on developing innovative therapies for the treatment of inflammatory diseases with large unmet medical needs. It is headquartered in Lausanne, Waadt, Switzerland.
For a complete picture of Tadekinig alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
